

Multiple Myeloma and Visceral Leishmaniasis: When and Why Differential Diagnosis May be Challenging

Giuseppe Bertuglia^{1,2}, Sara Bringham¹, Benedetto Bruno^{2,3} and Giulia Benevolo^{1,3*}

¹Department of Oncology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

²Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy

³Department of Hematology U, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

About the clinical case

Multiple Myeloma (MM) is commonly associated with immunoparesis, that consists in suppression of uninvolved polyclonal immunoglobulins, and immune cell dysregulation which may impair the ability to contrast pathogens. In addition, anti-MM therapy may cause neutropenia, lymphopenia and hypogammaglobulinemia, causing an increased susceptibility to opportunistic infections in these patients. Moreover, independently by the biochemical response, anti-myeloma therapy is often administered until progression or intolerance (e.g. lenalidomide maintenance) leading the immune system to an incomplete fully recovery.

Visceral *Leishmaniasis* (VL) is a vector-borne, mainly endemic, parasitic infection existing both in the zoonotic and the anthroponotic form. The zoonotic form, caused by *Leishmania infantum*, is the most frequent entity in Europe and it is transmitted through the bite of female hematophagous sand flies from the genus *Phlebotomus*. VL, which is potentially fatal without proper treatment, is characterized by intermittent fever, splenomegaly and weight loss combined to laboratory alterations such as hypergammaglobulinemia, elevated inflammatory markers and (pan) cytopenia. As we have previously reported, some common characteristics between MM and VL can lead to diagnostic-therapeutic mistakes. Let's try to analyse the key points of our case report in detail [1].

Polyclonal hypergammaglobulinemia is a common feature of VL; anyway, the detection of monoclonal paraproteins is exceptional but possible in this setting of patients. Indeed, several case reports beyond ours depicted VL as an etiology of both monoclonal gammopathy or reactive plasmacytosis in bone marrow firstly misdiagnosed with MM.

It is important to underline that monoclonal paraprotein may have an extremely long duration also after the infection resolution. These manifestations have been proposed to be a result of chronic

antigenic stimulation that occurs in these patients. Since host defense against *Leishmania* is mediated by T cells and T-cell-derived cytokines such as interferon gamma (IFN- γ) directed against infected macrophages, alterations of these mechanisms may promote the development of VL chronicity, as occurred in our patient [2]. Interestingly, paraproteins and hypergammaglobulinemia appeared when lenalidomide was suspended, probably due to reactivation of the immune system.

Hippocratic medicine considered error as an intrinsic element of diagnostics. Physicians who are influenced by long or frequent experiences with a certain kind of disease may be more likely led to a misleading diagnosis: The so called "availability bias". Indeed, all signs and symptoms (anaemia, fatigue and loss of appetite) were immediately associated to lenalidomide intolerance and, similarly, the increase of the paraprotein was associated to probable MM relapse. Conversely, splenomegaly wasn't sufficiently investigated by physicians, despite it was the key element to catch the correct diagnosis. During medical school studies, a lot of physicians are taught the old saying "when you hear hoof beats, think horses, not zebras", which means to consider first the most likely hypothesis during the diagnostic process. In a posteriori justification, the coexistence of splenomegaly, constitutional symptoms, cytopenia and the presence of monoclonal gammopathy, even with the absence of fever for the reasons above mentioned, should have suggested the probability of *Leishmania* infection, which is the "zebra" in endemic region.

In general, when the paraprotein is present in blood tests, the majority of physicians (haematologist or non-haematologist) believe the condition of Monoclonal Gammopathy of Undetermined Significance (MGUS) as an obligate precursor to several lymphoplasmacytic malignancies. Anyway, it must be considered the paraprotein is present in other non-hematologic conditions such as autoimmune disorders (Rheumatoid arthritis, Scleroderma, Hashimoto's thyroiditis), cutaneous diseases (Pyoderma gangrenosum, Necrobiotic xanthogranulomatosis), liver diseases (Hepatitis, cirrhosis) chronic infections (Tuberculosis, endocarditis) or in patients who underwent

*Address for Correspondence: Dr. Giulia Benevolo, Department of Oncology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy; E-mail: gbenevolo@cittadellasalute.to.it

Copyright: © 2024 Bertuglia G, et al. This is an open-access article distributed under the terms of the creative commons attribution license which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Received: 20-Feb-2024, Manuscript No. JBL-24-127927; Editor assigned: 23-Feb-2024, Pre QC No JBL-24-127927 (PQ); Reviewed: 07-Mar-2024, QC No JBL-23-127927; Revised: 14-Mar-2024, Manuscript No. JBL-24-127927 (R); Published: 21-Mar-2024, DOI: 10.37421/2165-7831.2024.14.316

organ transplantation [3]. For this reason, diagnostic work-up and long-term follow-up is generally recommended. Similarly, the absence of fever in our patient might be due to the above-mentioned dysregulation of the immune system, as reported in HIV-positive or post-transplant condition. Thus, the second key point to keep in mind is that even if fever is usually the alarm bell to suspect the presence of infection, not all infections present with fever. Indeed, in immunocompromised patients, the immune system may be anergic. whether the discovery of Acquired Immune Deficiency Syndrome (AIDS) in the 80s led to the knowledge of opportunistic infections, they should be also considered in patients who were treated with immunosuppressive drugs.

Moreover, we could assert that any clinical splenomegaly should be considered always pathological and it must be deeply investigate. In patients with splenomegaly of unknown origin and cytopenia, anti-Leishmania antibodies combined to DNA Leishmania research should be tested in endemic area. Finally, in blood diseases, a thorough bone marrow examination (aspiration and biopsy) remains the key diagnostic tool despite the advent of modern techniques. Another condition in which splenomegaly may be associated to paraprotein is POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, skin changes), a rare paraneoplastic syndrome caused by a clone of aberrant plasma cells; anyhow, polyneuropathy is a mandatory criterion and its absence exclude POEMS syndrome in differential diagnosis.

Currently, the risk to develop infections in MM and other hematologic malignancies, is increasing in the era of bispecific antibodies and Chimeric Antigen Receptor T-cell (CAR-T) therapy which may develop deep hypogammaglobulinemia or longer cytopenia [4]. Whether infections in MM are mainly caused by viruses and bacteria, fungal and also parasitic infections such as Strongyloidiasis, Trypanosomiasis, and Toxoplasmosis have rarely

been reported and their incidence may will increase in the future. Anyway, neither routine work-up or prophylaxis are recommended for parasitic infection, but they should be considered in the case of the exposed patient or in the endemic regions.

References

1. Benevolo Giulia, Giuseppe Bertuglia, Sara Bringham, Francesca Maletta, Benedetto Bruno, et al. "An a Typical Presentation Of Visceral Leishmaniasis Mimicking Multiple Myeloma Relapse." *Am J Hematol* 99(2024): 137-141.
2. Costa Da Silva, Ana Caroline, Danielle de Oliveira Nascimento and Jesuino RM Ferreira, et al. "Immune Responses in Leishmaniasis: An Overview". *Trop Med Infect Dis* 7(2022):1-16.
3. Go Ronald S and Vincent Rajkumar." How I Manage Monoclonal Gammopathy of Undetermined Significance". *Blood* 131(2018): 163-173.
4. Ludwig Heinz, Evangelos Terpos, Niels van de Donk and Maria-Victoria Mateos, et al. "Prevention and Management of Adverse Events during Treatment with Bispecific Antibodies and CAR T Cells in Multiple Myeloma: A Consensus Report of the European Myeloma Network". *Lancet Oncol* 24(2023):e255-e269.

How to cite this article: Bertuglia Giuseppe, Sara Bringham, Benedetto Bruno and Giulia Benevolo. "Multiple Myeloma and Visceral Leishmaniasis: When and Why Differential Diagnosis May be Challenging". *J Blood Lymph* (14): (1) (2024) :316